Thank you very much, Mr. Chair. At your request, I will keep my remarks in English.
Mr. Chair and honourable members, thank you for this opportunity to speak to the committee today about the health portfolio’s role in the government’s response to COVID-19.
The scope of COVID-19 has left no country untouched. Tragically, this pandemic has claimed thousands of lives worldwide, and Canada has not been immune. My heart goes out to all those who have lost a loved one here in Canada or elsewhere in the world.
During this unprecedented crisis, Canada has worked together to protect our health care systems and avoid the surges that have led to even greater loss of life in other countries. We must continue to work together to ensure that our health systems are fully prepared to care for Canadians as the world strives to find treatments and a vaccine. To do so effectively, we are collaborating with the provinces and territories to identify their needs and to help purchase required equipment, supplies and services.
We have taken an aggressive approach to buying, especially when it comes to personal protective equipment for front-line health care workers. This includes ordering in bulk on behalf of provinces and territories, supplementing these orders by purchasing everything immediately available that meets requirements, and galvanizing Canadian industries to increase domestic manufacturing capacity. These measures are over and above what the provinces and territories are doing to secure their own supplies.
The government is also coordinating shipments of supplies from other countries. Canada has established on-the-ground support in China for transportation, receiving, storage services and customs clearances.
Canada is receiving shipments, and the government is working to rapidly distribute personal protective equipment and medical supplies to the provinces and territories, using an approach agreed upon by federal, provincial and territorial ministers of health.
Provinces are proactively allocated 80% of shipments on a per capita basis, while 20% is held back for the national emergency strategic stockpile. This holdback is used to fulfill urgent requests for assistance from provinces and territories.
Furthermore, we know that early diagnosis is essential to slowing the spread of COVID-19 in Canada. That’s why in March I signed an interim order to allow expedited access to COVID-19-related medical devices, including diagnostic test kits. An interim order is one of the fastest mechanisms the government can use to help make health products available to address larger-scale public health emergencies. To date, we have authorized 19 tests under this interim order, tools that are necessary for our response to this pandemic.
The interim order also ensures that other COVID-19-related medical devices are available to treat, mitigate or prevent this disease. To help do this, the order allows Health Canada to review approvals granted by other countries when deciding whether to authorize a device for importation or sale. It also waives all application fees for COVID-19-related medical devices, further removing impediments for manufacturers in this time of public health need.
Mr. Chair, the health portfolio, in particular through the dedication of officials at the Public Health Agency of Canada, Health Canada, the Canadian Food Inspection Agency and the Canadian Institutes of Health Research, is committed to doing everything it can to protect the health and well-being of all Canadians.
I would like to conclude by thanking all of you, honourable members, for your ongoing work, collaboration and support to your constituents during this difficult time. Together we will continue to do everything we can to ensure that our country’s response continues to be effective and that we are equipped into the future.
Thank you.